EO
Evolus, Inc.
EOLS · NASDAQ
$7.86 -1.26% (-$0.10)
1M -6.32%
Market Cap $527.5M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$9.09
15.6% upside
Current Price
$7.86
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EOLS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
85 /100
Cheap P/S 1.67x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing Rev. growth 25.98%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak FCF margin 6.37%
Op. margin 7.33%
Gross margin 66.25%
Quality
21 /100
Poor ROA 13.84%
Asset turnover 1.28x
ROIC 15.57%
Debt
36 /100
Moderate Int. coverage -1.08x
Current ratio 1.70x
Net debt/EBITDA N/A
Stability
64 /100
Moderate Profitable years 0
EPS volatility 12.33%
Beta 1.43x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EOLS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
David Moatazedi
Employees
353
Headquarters
Newport Beach
Upcoming events
04 NOV
Earnings
Upcoming earnings report